PMID- 33220295
OWN - NLM
STAT- MEDLINE
DCOM- 20210225
LR  - 20211204
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 267
DP  - 2021 Feb 15
TI  - Tumor-regulated macrophage type 2 differentiation promotes immunosuppression in 
      laryngeal squamous cell carcinoma.
PG  - 118798
LID - S0024-3205(20)31551-4 [pii]
LID - 10.1016/j.lfs.2020.118798 [doi]
AB  - AIMS: Tumor-associated macrophage (TAM) residing in tumor microenvironment as the 
      major niche cell made remarkable contribution to tumor growth. However, the 
      functional role of macrophage and its different differentiating state as well as 
      the regulating mechanism in laryngeal squamous cell carcinoma (LSCC) remains not 
      fully clear. MATERIALS AND METHODS: LSCC samples were collected from patients. 
      Human peripheral blood mononuclear cells (PBMC) were collected from volunteers' 
      blood, and used for macrophage induction. Enzyme-Linked Immunosorbent Assay 
      (ELISA) was performed to detect proinflammatory cytokines. Immunostaining was 
      prepared to observe tumor tissues. KEY FINDINGS: Here, we found the number of 
      type 2 macrophage (MPhi2) and PDL-1 expression was increased in LSCC that was 
      correlated with poor prognosis in patients with LSCC. Tumor cells induced 
      macrophage into type 2 differentiation by TGF-beta/Smad3 signaling. The primed MPhi2 
      produced IL-10 by activating JAK/STAT signaling that promoted PDL-1 expression in 
      tumor cells leading to its immunosuppression. Inhibition of JAK/STAT signaling 
      promoted tumor cells death from immune cells killing by regulating PDL-1 
      expression. Targeting cytokines TGF-beta or IL-10 synergistically enhances the 
      sensitivity of tumors to chemotherapy in vivo. SIGNIFICANCE: In conclusion, our 
      findings showed tumor cells and MPhi2 were bilaterally regulated through cytokines 
      production that integrally advanced tumor progression through boosting anti-tumor 
      immunity. It provides insight to develop immune strategies synergy with 
      chemotherapy in treating laryngeal squamous cell carcinoma.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan, China. Electronic address: 
      fcczhangp1@zzu.edu.cn.
FAU - Zhang, Yanfei
AU  - Zhang Y
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan, China.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan, China.
FAU - Lou, Weihua
AU  - Lou W
AD  - Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan, China.
LA  - eng
PT  - Journal Article
DEP - 20201118
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (Cytokines)
RN  - 0 (STAT Transcription Factors)
RN  - EC 2.7.10.2 (Janus Kinases)
SB  - IM
MH  - B7-H1 Antigen/metabolism
MH  - Carcinoma, Squamous Cell/pathology
MH  - Cell Differentiation/immunology/physiology
MH  - Cell Proliferation
MH  - Cytokines/immunology/metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunosuppression Therapy
MH  - Janus Kinases/metabolism
MH  - Laryngeal Neoplasms/metabolism
MH  - Leukocytes, Mononuclear/metabolism
MH  - Macrophages/*immunology/metabolism
MH  - Male
MH  - STAT Transcription Factors/metabolism
MH  - Signal Transduction/physiology
MH  - Squamous Cell Carcinoma of Head and Neck/*immunology/metabolism
MH  - Tumor Microenvironment/immunology
MH  - Tumor-Associated Macrophages/immunology/*metabolism/physiology
OTO - NOTNLM
OT  - Immunosuppression
OT  - JAK/STAT signaling
OT  - Laryngeal squamous cell carcinoma
OT  - PDL-1
OT  - Tumor-associated macrophage type 2
EDAT- 2020/11/22 06:00
MHDA- 2021/02/26 06:00
CRDT- 2020/11/21 20:07
PHST- 2020/08/31 00:00 [received]
PHST- 2020/11/04 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
PHST- 2020/11/21 20:07 [entrez]
AID - S0024-3205(20)31551-4 [pii]
AID - 10.1016/j.lfs.2020.118798 [doi]
PST - ppublish
SO  - Life Sci. 2021 Feb 15;267:118798. doi: 10.1016/j.lfs.2020.118798. Epub 2020 Nov 
      18.